On April 13, 2023 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries (Press release, Twist Bioscience, APR 13, 2023, View Source [SID1234630071]). These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Twist CAR and TCR Libraries allow researchers and drug developers to fine tune these receptors to address the challenges of cell therapies, including off-target toxicity, enabling rapid advancement toward the clinic."

Twist TCR and CAR Libraries are large and diverse libraries made of up to 10,000 gene fragment combinations. This exceptional diversity enables high-throughput screening and characterization of novel and known sequence variants for therapeutic discovery. In these libraries, combinations of custom gene parts are shuffled to allow customers to test multiple elements at once, explore new combinations of variable binding regions and select candidates with the greatest therapeutic potential, accelerating the discovery phase and expediting the timeline to the clinic.

"While cell therapies have made a meaningful impact clinically, they have not yet reached their full potential," said Colin Farlow, CEO & Cofounder of Serotiny. "We partnered with Twist to accelerate progress toward our goal of engineering the next generation of cell therapies. Twist built CAR libraries of exceptional size and complexity that Serotiny utilized to discover synthetic receptors, aiming to decrease the costs and increase the effectiveness of cell therapies targeting solid tumors."

Twist TCR and CAR Libraries Production Workflow

Twist designs variations of customer selected DNA sequences. The sequences then go through the assembly process where custom gene parts are "shuffled." In TCR libraries, the alpha and beta chains are shuffled to create precise user-defined alpha and beta pairs or they can be shuffled into combinatorial pairs. In CAR libraries, variants of each domain are shuffled in a process called scaffold optimization. The variants are then cloned and sequenced. Before shipping to the customer, Twist uses next-generation sequencing to verify the entire library.

Presence at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023

Information about the Twist TCR and CAR Libraries will be available at the Twist booth at the AACR (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

In addition, Twist will present the following posters at the conference:

"Twist pan-cancer synthetic RNA fusion control for assay development", available for viewing Sunday, April 16 1:30-5:00 PM ET
"Human anti-CD40 agonistic antibodies with enhanced FcgR engagement activate immune cell and promote anti-tumor efficacy", available for viewing Monday, April 17 9:00-12:30 PM ET
"Discovery of a potent, selective, and tumor-suppressing antibody antagonist of DKK1", available for viewing Monday, April 17 1:30-5:00 PM ET
"High-sensitivity detection of specific ultra low-frequency somatic mutations for minimal residual disease monitoring", available for viewing Wednesday, April 19 9:30-12:30 PM ET
"An end-to-end workflow for improved methylation detection", available for viewing Wednesday, April 19 9:30-12:30 PM ET